Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 : Th2 cytokine ratios
- 1 January 2002
- journal article
- clinical trial
- Published by Wiley in Immunology
- Vol. 105 (1) , 56-62
- https://doi.org/10.1046/j.1365-2567.2002.01338.x
Abstract
Grass pollen immunotherapy is the only treatment for hayfever that is both effective and confers long-term benefit. Immunotherapy may act by altering the local nasal mucosal T helper type 2 (Th2) to type 1 (Th1) cytokine balance either by down-regulation and/or immune deviation of T-lymphocyte responses. There is controversy as to whether these changes are detectable in peripheral blood. We therefore examined both local nasal and peripheral T-cell responses to allergen exposure in the same subjects before and after immunotherapy. In a double-blind trial of grass pollen immunotherapy, nasal biopsies were obtained at baseline and during the peak pollen season following 2 years of immunotherapy. Placebo-treated patients showed a seasonal increase in CD3(+) T cells (P = 0.02) and in interleukin-5 (IL-5) mRNA(+) cells (P = 0.03) and no change in interferon-gamma (IFN-gamma ) mRNA(+) cells (P = 0.2) in the nasal mucosa. In contrast, in the immunotherapy-treated group, there were no changes in the number of CD3(+) T cells (P = 0.3) and IL-5 mRNA+ cells (P = 0.2) but a significant increase in the number of IFN-gamma mRNA(+) cells (P = 0.03). Furthermore, clinical improvement in the immunotherapy-treated group was accompanied by a seasonal increase in the ratio of IFN-gamma to IL-5 mRNA(+) cells in the nasal mucosa (P = 0.03). In contrast, there were no significant changes in peripheral T-cell proliferative responses or cytokine production for IFN-gamma or IL-5 in response to grass pollen either within or between the two treatment groups. We conclude that successful grass pollen immunotherapy was associated with an increase in the ratio of IFN-gamma to IL-5 mRNA(+) cells in the nasal mucosa, whereas these changes were not reflected by alterations in peripheral blood T-cell proliferative responses or cytokine production before/after treatment.Keywords
This publication has 46 references indexed in Scilit:
- Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trialJournal of Allergy and Clinical Immunology, 2001
- Role of interleukin 10 in specific immunotherapy.Journal of Clinical Investigation, 1998
- Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy☆☆☆★★★Journal of Allergy and Clinical Immunology, 1997
- Changes in Allergic Inflammation Associated with Successful ImmunotherapyInternational Archives of Allergy and Immunology, 1995
- Activation of CD4+ T cells, increased T-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthmaJournal of Allergy and Clinical Immunology, 1993
- Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.Journal of Clinical Investigation, 1993
- Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavityJournal of Allergy and Clinical Immunology, 1991
- Evidence suggesting involvement of interleukin-4 (IL-4) production in spontaneous in vitro IgE synthesis in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1991
- Changes in nasal metachromatic cells during allergen immunotherapyClinical and Experimental Allergy, 1991
- IgG Subclass Antibody Response in Grass Pollen‐Allergic Patients Undergoing Specific ImmunotherapyAllergy, 1984